Means Investment CO. Inc. Grows Stock Holdings in Johnson & Johnson (NYSE:JNJ)


Share on StockTwits

Means Investment CO. Inc. boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.1% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 29,294 shares of the company’s stock after buying an additional 318 shares during the quarter. Johnson & Johnson makes up 1.1% of Means Investment CO. Inc.’s holdings, making the stock its 20th biggest position. Means Investment CO. Inc.’s holdings in Johnson & Johnson were worth $4,814,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. SYM FINANCIAL Corp raised its position in Johnson & Johnson by 3.7% in the 4th quarter. SYM FINANCIAL Corp now owns 1,729 shares of the company’s stock valued at $272,000 after purchasing an additional 62 shares during the last quarter. Financial Advisors Network Inc. raised its position in Johnson & Johnson by 2.4% in the 4th quarter. Financial Advisors Network Inc. now owns 2,686 shares of the company’s stock valued at $423,000 after purchasing an additional 62 shares during the last quarter. Mather Group LLC. raised its position in Johnson & Johnson by 0.6% in the 4th quarter. Mather Group LLC. now owns 10,235 shares of the company’s stock valued at $1,611,000 after purchasing an additional 62 shares during the last quarter. Gateway Advisory LLC raised its position in Johnson & Johnson by 2.1% during the 4th quarter. Gateway Advisory LLC now owns 3,054 shares of the company’s stock worth $481,000 after buying an additional 63 shares during the last quarter. Finally, Oak Asset Management LLC raised its position in Johnson & Johnson by 0.3% during the 4th quarter. Oak Asset Management LLC now owns 23,761 shares of the company’s stock worth $3,740,000 after buying an additional 70 shares during the last quarter. Institutional investors own 67.25% of the company’s stock.

A number of brokerages have commented on JNJ. Wells Fargo & Company upped their price objective on shares of Johnson & Johnson from $175.00 to $190.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 27th. SVB Leerink upped their price objective on shares of Johnson & Johnson from $180.00 to $200.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 27th. Cantor Fitzgerald upped their price objective on shares of Johnson & Johnson from $180.00 to $200.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 26th. Credit Suisse Group upped their price objective on shares of Johnson & Johnson from $168.00 to $193.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 27th. Finally, Raymond James upped their price target on shares of Johnson & Johnson from $158.00 to $183.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 27th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $178.60.

NYSE:JNJ traded up $0.01 on Thursday, reaching $163.62. The stock had a trading volume of 70,805 shares, compared to its average volume of 8,177,090. The company has a market cap of $430.76 billion, a price-to-earnings ratio of 25.76, a P/E/G ratio of 3.06 and a beta of 0.70. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.48 and a quick ratio of 1.24. The firm’s fifty day moving average is $161.06 and its two-hundred day moving average is $154.38. Johnson & Johnson has a 12-month low of $133.65 and a 12-month high of $173.65.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Monday, January 25th. The company reported $1.86 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.82 by $0.04. The company had revenue of $22.50 million for the quarter, compared to analyst estimates of $21.62 billion. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The firm’s quarterly revenue was up 8.7% on a year-over-year basis. During the same period in the prior year, the firm earned $1.88 EPS. As a group, research analysts forecast that Johnson & Johnson will post 7.99 earnings per share for the current fiscal year.

About Johnson & Johnson

Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More: Do back-end load funds outperform no-load funds?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.